Focus: Cancer Center Featured Story 2

Filters close
Released: 7-Apr-2020 10:40 AM EDT
Dana-Farber scientists bring experience from SARS and MERS outbreaks to aid COVID-19 research
Dana-Farber Cancer Institute

As scientists race to develop and test new treatments for COVID-19, Dana-Farber’s Wayne Marasco, MD, PhD, and his lab team are bringing one of the world’s most formidable resources to the effort: a “library” of 27 billion human antibodies against viruses, bacteria, and other bodily invaders.The collection, created by Marasco and his associates in 1997 using blood samples from more than 57 Dana-Farber staff, has already had an illustrious history in the quest to tame viral disease outbreaks.

Released: 7-Apr-2020 10:20 AM EDT
Alleviating Confusion around Pain Management Recommendations
National Comprehensive Cancer Network® (NCCN®)

New information from NCCN, ASCO, ASH, CDC, FDA, and others seeks to provide clear guidance on how to optimally manage cancer-related pain without exacerbating the ongoing opioid crisis—published jointly in the Journal of the National Comprehensive Cancer Network and JCO Oncology Practice.

Newswise: New mental health challenges for cancer patients during COVID-19
Released: 6-Apr-2020 12:05 PM EDT
New mental health challenges for cancer patients during COVID-19
University of Colorado Cancer Center

Benjamin Brewer, PsyD, is a University of Colorado Cancer Center investigator and health psychologist at the UCHealth University of Colorado Hospital Bone Marrow Transplant Program. Here CU Cancer Center talks with Dr. Brewer about his patients’ new worries and about how our health system is adapting to meet the mental health needs of cancer patients during COVID-19.

Released: 3-Apr-2020 4:05 PM EDT
Roswell Park Reports Extended Survival Among Breast Cancer Survivors Who Exercise Regularly
Roswell Park Comprehensive Cancer Center

New research from Roswell Park Comprehensive Cancer Center, published in the Journal of the National Cancer Institute, shows that following those guidelines can improve clinical outcomes for patients with high-risk breast cancer, or breast cancer that is likely to recur or spread.

Newswise: Rutgers Cancer Institute Offers Clinical Trial Examining Potential Treatment for COVID-19
Released: 3-Apr-2020 1:35 PM EDT
Rutgers Cancer Institute Offers Clinical Trial Examining Potential Treatment for COVID-19
Rutgers Cancer Institute of New Jersey

Rutgers Cancer Institute of New Jersey, a National Cancer Institute-designated Comprehensive Cancer Center, is offering a clinical trial as a potential treatment for patients diagnosed with the coronavirus (COVID-19). The trial, which is not limited to cancer patients is exploring hydroxychloroquine and azithromycin.

Released: 3-Apr-2020 8:10 AM EDT
Tip Sheet: Tracking COVID-19, protein design, TB vaccines, a new brain map and more
Fred Hutchinson Cancer Research Center

Summaries of recent Fred Hutch research findings with links for additional background and media contacts.

Newswise: Colorado study overturns ‘snapshot’ model of cell cycle in use since 1974
Released: 2-Apr-2020 3:05 PM EDT
Colorado study overturns ‘snapshot’ model of cell cycle in use since 1974
University of Colorado Cancer Center

Live, single-cell imaging shows that cells continuously integrate the influence of growth factors, not just during G1 phase of cell cycle, as previously thought.

Newswise: Majority of patients responded in CAR T-cell trial for mantle cell lymphoma
30-Mar-2020 12:20 PM EDT
Majority of patients responded in CAR T-cell trial for mantle cell lymphoma
University of Texas M. D. Anderson Cancer Center

Majority of patients responded in CAR T-cell trial for mantle cell lymphoma. Study showed 93% of patients responded with 67% achieving complete response.

Newswise: Immunotherapy effective in metastatic prostate cancers with specific markers of immune activation
30-Mar-2020 2:40 PM EDT
Immunotherapy effective in metastatic prostate cancers with specific markers of immune activation
University of Texas M. D. Anderson Cancer Center

A subset of patients with metastatic prostate cancer and specific markers of immune activity responded well to treatment with immune checkpoint inhibitors, according to results of a Phase II trial.


Showing results

110 of 10

close
1.53133